A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

被引：28
|
作者：
Sangro, Bruno
Park, Joong-Won
Dela Cruz, Christine Marie
Anderson, Jeffrey
Lang, Lixin
Neely, Jaclyn
Shaw, James W.
Cheng, Ann-Lii
机构：
[1] Clin Univ Navarra & CIBERHD, Liver Unit, Pamplona, Spain
[2] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4147
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Cheng, Ann-Lii
    Thongprasert, Sumitra
    Lim, Ho Yeong
    Sukeepaisarnjaroen, Wattana
    Yang, Tsai-Sheng
    Wu, Cheng-Chung
    Chao, Yee
    Chan, Stephen Lam
    Kudo, Masatoshi
    Ikeda, Masafumi
    Kang, Yoon-Koo
    Pan, Hongming
    Numata, Kazushi
    Han, Guohong
    Balsara, Binaifer
    Zhang, Yong
    Rodriguez, Ana-Maria
    Zhang, Yi
    Wang, Yongyu
    Poon, Ronnie Tung-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [42] Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
    Wang, Emilie
    Kim, Dae Won
    Mahipal, Amit
    Chen, Dung-Tsa
    Cao, Biwei
    Masawi, Fadzai
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    He, Aiwu Ruth
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Hung, Chao-Hung
    Sheen, I-Shyan
    Izumi, Namiki
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Shiratori, Shinichi
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 896 - 904
  • [44] Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Pazo Cid, R. A.
    Esquerdo, G.
    Puertolas, T.
    Calderero, V.
    Gil, I.
    Lao, J.
    Millastre, E.
    Alvarez-Alejandro, M.
    Madani, J.
    Anton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040
    Sangro, Bruno
    Melero, Ignacio
    Yau, Thomas
    Hsu, Chiun
    Kudo, Masatoshi
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H.
    Meyer, Timothy
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Baakili, Adyb
    dela Cruz, Christine
    Zhao, Huanyu
    Neely, Jaclyn
    Crocenzi, Todd S.
    El-Khoueiry, Anthony B.
    HEPATOLOGY, 2017, 66 : 82A - 82A
  • [46] Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Study
    Johnson, Phillip
    Qin, Shukui
    Park, Joong-Won
    Poon, Ronnie T.
    Raoul, Jean-Luc
    Philip, Philip A.
    Hsu, Chih-Hung
    Hu, Tsung-Hui
    Heo, Jeong
    Xu, Jianming
    Lu, Ligong
    Chao, Yee
    Boucher, Eveline
    Han, Kwang-Hyub
    Paik, Seung Woon
    Robles-Avina, Jorge
    Kudo, Masatoshi
    Liu, David
    Ezzeddine, Rana
    Walters, Ian
    Cheng, Ann-Lii
    HEPATOLOGY, 2012, 56 (06) : 1519 - 1520
  • [47] Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
    Hsu, Chih-Hung
    Kang, Yoon Koo
    Yang, Tsai-Shen
    Shun, Chia-Tung
    Shao, Yu-Yun
    Su, Wu-Chou
    Sandoval-Tan, Jennifer
    Chiou, Tzeon-Jye
    Jin, Kate
    Hsu, Chiun
    Cheng, Ann-Lii
    ONCOLOGY, 2013, 85 (01) : 44 - 52
  • [48] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
    Galle, Peter Robert
    Decaens, Thomas
    Kudo, Masatoshi
    Qin, Shukui
    Fonseca, Leonardo
    Sangro, Bruno
    Karachiwala, Hatim
    Park, Joong-Won
    Gane, Edward
    Pinter, Matthias
    Tai, David
    Santoro, Armando
    Pizarro, Gonzalo
    Chiu, Chang-Fang
    Schenker, Michael
    He, Aiwu Ruth
    Wang, Qi
    Stromko, Caitlyn
    Hreiki, Joseph
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
  • [49] Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials
    Brown, Timothy J.
    Gupta, Arjun
    Sedhom, Ramy
    Beg, Muhammad S.
    Karasic, Thomas B.
    Yarchoan, Mark
    GASTROINTESTINAL TUMORS, 2022, 9 (01) : 19 - 26
  • [50] Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation
    Nguyen, Dung Thi
    Nguyen, Duong Hoang
    Nguyen, Van Thi Hong
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (06)
12345